Santander

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Coronary artery disease3 trials
• Familial hypercholesterolaemia3 trials
• Stroke3 trials
• Multiple myeloma2 trials
• Acute myeloid leukaemia1 trial
• Chronic myeloid leukaemia1 trial
• Colorectal cancer1 trial
• Dermatomyositis and polymyositis (myositis)1 trial
• Multiple sclerosis1 trial
• Myelodysplastic syndromes1 trial

Phase

• Phase 24 trials
• Phase 34 trials
• Phase 12 trials

Status

• Active, not recruiting5 trials
• Terminated4 trials
• Completed3 trials

Lead sponsor

• Novartis Pharmaceuticals12 trials

Running trials

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study

  NCT06958315· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Phase 2 Study of Rapcabtagene Autoleucel in Myositis

  NCT06665256· Phase 2· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

  NCT05739383· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

  NCT05030428· Phase 3· Novartis Pharmaceuticals· Source

Closed trials

• Completed

  A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice

  NCT06251986· Novartis Pharmaceuticals· Source

• Terminated

  Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC

  NCT04952753· Phase 2· Novartis Pharmaceuticals· Source

• Terminated

  VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)

  NCT04702425· Phase 1· Novartis Pharmaceuticals· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Novartis Pharmaceuticals· Source

• Terminated

  A Study of WVT078 in Patients With Multiple Myeloma (MM)

  NCT04123418· Phase 1· Novartis Pharmaceuticals· Source

• Terminated

  A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).

  NCT03946670· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

  NCT01698905· Phase 2· Novartis Pharmaceuticals· Source